The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).
- DOI
- 10.1016/j.neo.2026.101316
- Published
- 2026 Sep
- Container
- Neoplasia (New York, N.Y.)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.neo.2026.101316,
title = {The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).},
author = {Hopley PJ and Boughey A and Bullock K and Greenhalf W and Halloran CM},
year = {2026},
journal = {Neoplasia (New York, N.Y.)},
doi = {10.1016/j.neo.2026.101316},
url = {https://doi.org/10.1016/j.neo.2026.101316}
}RIS
TY - JOUR TI - The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS). AU - Hopley PJ AU - Boughey A AU - Bullock K AU - Greenhalf W AU - Halloran CM PY - 2026 JO - Neoplasia (New York, N.Y.) DO - 10.1016/j.neo.2026.101316 UR - https://doi.org/10.1016/j.neo.2026.101316 ER -
APA
PJ, H., A, B., K, B., W, G., & CM, H. (2026). The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).. Neoplasia (New York, N.Y.). https://doi.org/10.1016/j.neo.2026.101316
Source records
- pubmed · retrieved 2026-09-26T12:30:08.059Z
- europe-pmc · retrieved 2026-09-26T12:30:08.062Z
- doaj · retrieved 2026-09-26T12:30:08.037Z